. Results of the WOMAC scores (Median and 25 th -75 th percentiles) preoperatively and at the 2, 6, and 12-month follow-ups.
Results: Self-reported disability and pain declined, objectively measured physical performance, and HRQoL improved significantly in both groups. No difference was found between groups in any outcome measure during the study period. The results of the WOMAC scores are presented in Figure 1 . In the 15D score participants in both groups reached the level of the general public of the same age at the 12-month follow-up. The absolute change in 3 physical domain scales of the RAND-36 (PF, BP and RP) during the study period was 20 in both groups, indicating significant clinical improvement. Remarkable improvement, which plateaued at 6 months, was found in the results of all physical performance tests. No difference was found between groups in the use of additional postoperative rehabilitation services (p = 0.77). According to the OMERACT-OARSI criteria high improvement was detected in 26 (72.2%) participants of the AG, and in 27 (69.2%) participants of the CG at the 12-month-follow-up. Conclusions: The MRP 2−4 months after TKA did not yield faster attainment of functional recovery than did standard orthopedic care alone. Dramatic improvement in functional ability, pain, HRQoL, and physical performance was gained in both groups within the first 6 months after surgery. Purpose: In the synovial fluid (SF) of patients suffering from osteoarthritis (OA) a decrease in the concentration and in the molecular weight of hyaluronan can be observed. Therefore, treatment of OA includes intraarticular injections of hyaluronan whereby the viscoelastic properties of the SF are believed to be restored. During the past years it has, however, become evident that the mechanism of action of intra-articular injections of hyaluronan may be more than this; important interactions with hyaluronan binding proteins and receptors may be involved. For this to take place, the injected product needs to be recognized as hyaluronan by the body. Current hyaluronan products for OA treatment include solutions of purified hyaluronan as well as hyaluronan hydrogels, where the material has been crosslinked into networks. Some of the hydrogels have been suggested to be less biocompatible than others, which may depend on e.g. the source and purity of the ingoing material. In addition, the chemical structure of the crosslinked polysaccharide and thus the ability of the body to recognise it as hyaluronan may vary substantially. In the present study, (i) the biocompatibility of Durolane TM in the joint and (ii) the ability of proteins that bind hyaluronan with high specificity, to interact with Durolane in vitro, has been investigated. Durolane is composed of hyaluronan of bacterial origin that has been crosslinked into a network by Q-Meds patented NASHA TM manufacturing process. The product has the appearance of a clear gel composed of small gel particles. Methods: Biocompatibility; Durolane was injected into the knee of anesthetized rabbits. This was repeated after 6 and 12 weeks (a total of three injections). The animals were observed for adverse events, and knee joint capsules were sectioned and studied microscopically. Protein interactions; A complex (containing the hyaluronan binding Link module) was purified from cartilage and labelled with Alexa-Fluor ® 594 (HABCfl). Durolane gel particles were incubated at room temperature in PBS containing 75 mg/ml of HABCfl and viewed by confocal microscopy. Probe pre-incubated with hyaluronan oligosaccharides was used as a negative control. The degradation of Durolane by hyaluronidase was monitored by the use of ultra filtration and detection of released hyaluronic acid (HA) oligomers using carbazole. A solution of hyaluronan of the same concentration was degraded at the same time and by the same conditions, as a reference. Results: Biocompatibility studies revealed no evidence of infiltration of inflammatory cells, necrosis, irritation or any deleterious inflammatory reactions within the joint capsule and within the surrounding tissue. In the confocal microscope, particles of Durolane appeared strongly fluorescent after incubation with HABCfl. The specific nature of the interaction was confirmed by the negative controls which were devoid of fluorescence. In the hyaluronidase assay, Durolane exhibited the same degradation profile as the solution of hyaluronan.
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Conclusions: Durolane appears to be safe and without adverse reactions when used for intra-articular injections. In addition, the gel could be recognised by proteins containing the LINK module conferring normal hyaluronan binding. Thus hyaluronan present in Durolane can interact with hyaluronan binding proteins and is likely to confer the same signals as endogenous hyaluronan.
